Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8071 to 8085 of 8216 results

  1. Depemokimab for treating severe eosinophilic asthma in people 12 years and over TSID 12017

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

    In development [GID-HTE10035] Expected publication date: TBC

    Health technology evaluations
    In development

  3. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  4. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  5. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: 07 August 2024

    Technology appraisal guidance
    In development

  6. Robot-assisted surgery for orthopaedic procedures: early value assessment

    In development [GID-HTE10043] Expected publication date: 21 January 2025

    Health technology evaluations
    In development

  7. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Zoll ThermoGuard XP for Intravascular Temperature Management

      Status ...

    Medical technologies guidance
    Topic selection

  11. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  12. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]

    In development [GID-TA10699] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

    In development [GID-TA11187] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  15. Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]

    In development [GID-TA11554] Expected publication date: TBC

    Technology appraisal guidance
    In development